Heart valve mechanical prosthesis: The perfect match until it is not - A case report

Movileanu,Ionela; Pepa,Miruna; Cândea,Marcela; Ureche,Corina

doi:10.3892/etm.2020.8959

Heart valve mechanical prosthesis: The perfect match until it is not - A case report

Authors:
- Ionela Movileanu
- Miruna Pepa
- Marcela Cândea
- Corina Ureche
View Affiliations

Affiliations: First Cardiology Department, Emergency Institute of Cardiovascular Diseases and Transplant, 540136 Târgu Mureș, Romania, First Internal Medical Department, ‘George Emil Palade’ University of Medicine, Pharmacy, Sciences and Technology, 540136 Târgu Mureș, Romania
Published online on: June 29, 2020 https://doi.org/10.3892/etm.2020.8959
Pages: 2481-2483

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primary immune thrombocytopenia (ITP), formerly known as idiopathic thrombocytopenia, is defined by a reduced platelet count <50x109 and is clinically manifested through signs and symptoms such as bleeding, ecchymosis and petechiae. Its coexistence with the implantation of the mechanical valves and the necessity of anticoagulation creates an additional risk of bleeding. Although mechanical valves are indispensable in prolonging and improving the quality of life in patients with valvular heart disease, in the context of an additional bleeding risk factor, their presence could represent a threat to life exposing the patient to major complications and leading to death. The purpose of this case report is to discuss the disadvantages and possible fatal complications of the association between mechanical valves and severe thrombocytopenia. A possible solution to these downsides could be found in the future search in regenerative medicine and tissue engineering of heart valves resulting in products that do not require anticoagulation and do not pose a threat to patients with thrombocytopenia.

View Figures

View References

1	Vangeldorp M, Jamieson WRE, Kappetein AP, Ye J, Fradet GJ, Eijkemans MJC, Grunkemeier GL, Bogers JJC and Takkenberg JJM: Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: Weighing lifetime anticoagulant-related event risk against reoperation risk. J Thorac Cardiovasc. 37:881–886. 2009.PubMed/NCBI View Article : Google Scholar
2	Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al: Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group. Blood. 113:2386–2393. 2009.PubMed/NCBI View Article : Google Scholar
3	Neylon AJ, Saunders PW, Howard MR, Proctor SJ and Taylor PR: Northern Region Haematology Group: Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: A prospective study of a population-based cohort of 245 patients. Br J Haematol. 122:966–974. 2003.PubMed/NCBI View Article : Google Scholar
4	Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS and Logie J: The incidence of idiopathic thrombocytopenic purpura among adults: A population-based study and literature review. Eur J Haematol. 83:83–89. 2009.PubMed/NCBI View Article : Google Scholar
5	McCrae K: Immune thrombocytopenia: No longer ‘idiopathic’. Cleve Clin J Med. 78:358–373. 2011.PubMed/NCBI View Article : Google Scholar
6	Piccardo A, Rusinaru D, Petitprez B, Marticho P, Vaida I, Tribouilloy C and Caus T: Thrombocytopenia after aortic valve replacement with freedom solo bioprosthesis: A propensity study. Ann Thorac Surg. 89:1425–1430. 2010.PubMed/NCBI View Article : Google Scholar
7	Mujtaba SS, Ledingham S, Shah AR, Schueler S, Clark S and Pillay T: Thrombocytopenia after aortic valve replacement: Comparison between sutureless perceval S Valve and Perimount Magna Ease Bioprosthesis. Braz J Cardiovasc Surg. 33:169–175. 2018.PubMed/NCBI View Article : Google Scholar
8	Kizilay M, Elbir F, Aglar AA, Vural U, Balci AY and Yekeler İ: An overlooked fact: Thrombocytopenia following bioprosthetic aortic valve replacement. Kardiochir Torakochirurgia Pol. 16:19–26. 2019.(In Polish). PubMed/NCBI View Article : Google Scholar
9	Corbett TL, Elher KS and Garwood CL: Successful use of fondaparinux in a patient with a mechanical heart valve replacement and a history of heparin-induced thrombocytopenia. J Thromb Thrombolysis. 30:375–377. 2010.PubMed/NCBI View Article : Google Scholar
10	Warkentin TE, Greinacher A, Koster A and Lincoff AM: Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 133:S340–S380. 2008.PubMed/NCBI View Article : Google Scholar
11	Emery RW, Krogh CC, Arom KV, Emery AM, Benyo-Albrecht K, Joyce LD and Nicoloff DM: The St. Jude Medical cardiac valve prosthesis: A 25-year experience with single valve replacement. Ann Thorac Surg. 79:776–782; discussion 782-783. 2005.PubMed/NCBI View Article : Google Scholar
12	Salem DN, O'Gara PT, Madias C and Pauker SG: Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 133:S593–S629. 2008.PubMed/NCBI View Article : Google Scholar
13	Tardalkar K, Desai S, Adnaik A, Bohara R and Joshi M: Novel approach toward the generation of tissue engineered heart valve by using combination of antioxidant and detergent: A potential therapy in cardiovascular tissue engineering. Tissue Eng Regen Med. 14:755–762. 2017.PubMed/NCBI View Article : Google Scholar
14	Zhang BL, Bianco RW and Schoen FJ: Preclinical assessment of cardiac valve substitutes: Current status and considerations for engineered tissue heart valves. Front Cardiovasc Med. 6(72)2019.PubMed/NCBI View Article : Google Scholar
15	Movileanu I, Brinzaniuc K, Harpa M, Nistor D, Cotoi O, Preda T, Al Hussein H, Moldovan O, Man A, Harceaga L, et al: Pressurized perfusion system for obtaining completely acellular pulmonary valve scaffolds for tissue engineering. ARS Med Tomitana. 25:149–156. 2019.
16	Harpa M, Movileanu I, Sierad L, Cotoi O, Suciu H, Preda T, Nistor D, Sircuța C, Brânzaniuc K, Deac R, et al: In vivo testing of xenogeneic acellular aortic valves seeded with stem cells. Rev Rom Med Lab. 24:343–346. 2016.PubMed/NCBI View Article : Google Scholar
17	Reimer J, Syedain Z, Haynie B, Lahti M, Berry J and Tranquillo R: Implantation of a tissue-engineered tubular heart valve in growing lambs. Ann Biomed Eng. 45:439–451. 2017.PubMed/NCBI View Article : Google Scholar
18	Boethig D, Horke A, Hazekamp M, Meyns B, Rega F, Van Puyvelde J, Hübler M, Schmiady M, Ciubotaru A, Stellin G, et al: A European study on decellularized homografts for pulmonary valve replacement: Initial results from the prospective ESPOIR Trial and ESPOIR Registry data. Eur J Cardio-Thorac Surg. 56:503–509. 2019.PubMed/NCBI View Article : Google Scholar